SubsidieMeestersHuman genetic determinants of invasive group A streptococcal host-pathogen interactions
This project aims to identify genetic factors that increase susceptibility to invasive Group A streptococcus infections by integrating human genetics with host-pathogen interaction studies.
Projectdetails
Introduction
Group A streptococcus (GAS) is a major, human-specific bacterial pathogen. Most people suffer from mild infections, while only a few develop invasive GAS (iGAS) infections. These cases of iGAS infections are unexplained as they strike otherwise healthy people. The human specificity of GAS and the interindividual variability upon infection with GAS are poorly understood. My proposal aims to close both knowledge gaps: I hypothesize that single-gene defects of antistreptococcal immunity increase susceptibility to human-specific GAS virulence factors in some people, thereby underlying their iGAS infections.
Project Framework
I propose an innovative framework to unravel iGAS pathophysiology in humans by applying a strategy to integrate the studies of human genetics and host-pathogen interactions at the molecular level. This project focuses on patients suffering from iGAS infections.
Patient Recruitment and Data Collection
Most patients have been enrolled, sampled, and whole exome sequencing (WES) performed. Additional patients will be recruited. The human gene(s) underlying iGAS infections will be identified using complementary WES-based approaches.
Molecular Dissection
The discovered inborn error(s) of immunity to GAS and the host-pathogen interactions will be dissected at the molecular, cellular, tissue, and whole-organismal levels, including with patients’ cells and clinical GAS strains.
Data Availability
The immediate availability of patients’ genetic data provides a secure starting point for an efficient implementation of this proposal. Preliminary analyses have yielded two promising candidate genes.
Specimen Access
Access to patients’ specimens and clinical GAS isolates offers an exceptional opportunity to characterize patient-specific host-pathogen interactions. Thus, we are in a unique position to discover the first human genetic determinant(s) of iGAS host-pathogen interactions.
Potential Impact
This project may uncover the role of genes in human physiology beyond the infectious phenotype and accelerate the development of preventative strategies against GAS infections.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 1.496.978 |
| Totale projectbegroting | € 1.496.978 |
Tijdlijn
| Startdatum | 1-1-2025 |
| Einddatum | 31-12-2029 |
| Subsidiejaar | 2025 |
Partners & Locaties
Projectpartners
- UNIVERSITAIR MEDISCH CENTRUM UTRECHTpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
In situ genetic perturbation of gut bacteria with engineered phage vectors and CRISPRThis project aims to develop synthetic biology tools for precise genetic manipulation of gut bacteria using phage vectors and CRISPR-Cas systems to enhance microbiome-targeted therapies. | ERC Consolid... | € 1.999.780 | 2022 | Details |
Systematic Triangulation of Pathobiont-Host-InteractionsThe project aims to identify disease-driving pathobionts linked to genetic risk factors in IBD and CRC using high-throughput technology and machine learning to enhance precision medicine. | ERC Starting... | € 1.993.688 | 2024 | Details |
Isotopically labelling of cell surface glycans to illuminate infectious processes at atomic resolutionGlyco13Cell aims to chemically remodel cell surface glycans using NMR probes to enhance understanding of glycan-lectin interactions for developing novel tools in infectious disease treatment. | ERC Starting... | € 1.500.000 | 2023 | Details |
Understanding respiratory tract infections through minimally-invasive, daily nasal sampling in childrenThis project aims to elucidate the immune and microbiota factors influencing upper respiratory tract infections in children through innovative nasal sampling and multi-omics analyses, enhancing diagnostics and public health strategies. | ERC Starting... | € 1.677.858 | 2023 | Details |
Dissecting the context-specificity of genetic immune regulation in plasmacytoid dendritic cellsThe project aims to uncover the genetic regulation and functional diversity of plasmacytoid dendritic cells to explain variability in antiviral responses and autoimmune diseases across diverse populations. | ERC Starting... | € 1.499.235 | 2023 | Details |
In situ genetic perturbation of gut bacteria with engineered phage vectors and CRISPR
This project aims to develop synthetic biology tools for precise genetic manipulation of gut bacteria using phage vectors and CRISPR-Cas systems to enhance microbiome-targeted therapies.
Systematic Triangulation of Pathobiont-Host-Interactions
The project aims to identify disease-driving pathobionts linked to genetic risk factors in IBD and CRC using high-throughput technology and machine learning to enhance precision medicine.
Isotopically labelling of cell surface glycans to illuminate infectious processes at atomic resolution
Glyco13Cell aims to chemically remodel cell surface glycans using NMR probes to enhance understanding of glycan-lectin interactions for developing novel tools in infectious disease treatment.
Understanding respiratory tract infections through minimally-invasive, daily nasal sampling in children
This project aims to elucidate the immune and microbiota factors influencing upper respiratory tract infections in children through innovative nasal sampling and multi-omics analyses, enhancing diagnostics and public health strategies.
Dissecting the context-specificity of genetic immune regulation in plasmacytoid dendritic cells
The project aims to uncover the genetic regulation and functional diversity of plasmacytoid dendritic cells to explain variability in antiviral responses and autoimmune diseases across diverse populations.